Blood test may guide Post-Surgery cancer treatment
NCT ID NCT06609759
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 197 people with stage II-III gastric cancer who had surgery. Researchers want to see if using a blood test (ctDNA) to guide post-surgery treatment works as well as standard chemotherapy. The goal is to learn if some patients can safely receive less intense treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- standard chemotherapy regimen
- What this could lead to
- If successful, this could show that using a ctDNA blood test to guide treatment is as effective as standard chemotherapy, potentially allowing some patients to receive less intense therapy.
- What could go wrong
- This is an observational study, not a randomized trial, so results may not prove cause and effect. The findings are preliminary and need confirmation in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II-III GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinan Central Hospital,
Jinan, Shandong, China
-
Qilu Hospital of Shandong Univertisy
Jinan, Shandong, 250012, China
-
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, 250012, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266000, China
-
Yantai Yuhuangding Hospital
Yantai, Shandong, 264000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.